Trial Profile
A Randomized, Phase II Multicenter Trial Evaluating the Efficacy and Safety of a Systemic Hedgehog Pathway Antagonist (GDC-0449) in Patients With Basal Cell Nevus Syndrome (BCNS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer; Basal cell nevus syndrome
- Focus Therapeutic Use
- Acronyms GDC-0449
- 09 Nov 2016 Primary endpoint has been met. (To evaluate the efficacy of GDC-0449 in reducing new surgically eligible BCCs in BCNS patients during month 3-18 of ingestion of 150 mg/day.)
- 09 Nov 2016 Final results of this 36 month published in the Lancet Oncology
- 07 Jun 2012 Results have been published in the New England Journal of Medicine according to a Curis media release.